|
1
|
Caldwell S and Park SH: The epidemiology
of hepatocellular cancer: From the perspectives of public health
problem to tumor biology. J Gastroenterol. 44 (Suppl 19):S96–S101.
2009. View Article : Google Scholar
|
|
2
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Finn RS, Qin S, Ikeda M, Galle PR, Ducreux
M, Kim TY, Kudo M, Breder V, Merle P, Kaseb AO, et al: Atezolizumab
plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J
Med. 382:1894–1905. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kudo M, Finn RS, Qin S, Han KH, Ikeda K,
Piscaglia F, Baron A, Park JW, Han G, Jassem J, et al: Lenvatinib
versus sorafenib in first-line treatment of patients with
unresectable hepatocellular carcinoma: A randomised phase 3
non-inferiority trial. Lancet. 391:1163–1173. 2018. View Article : Google Scholar
|
|
5
|
El-Khoueiry AB, Sangro B, Yau T, Crocenzi
TS, Kudo M, Hsu C, Kim TY, Choo SP, Trojan J, Welling TH Rd, et al:
Nivolumab in patients with advanced hepatocellular carcinoma
(CheckMate 040): An open-label, non-comparative, phase 1/2 dose
escalation and expansion trial. Lancet. 389:2492–2502. 2017.
View Article : Google Scholar
|
|
6
|
Zhu AX, Finn RS, Edeline J, Cattan S,
Ogasawara S, Palmer D, Verslype C, Zagonel V, Fartoux L, Vogel A,
et al: Pembrolizumab in patients with advanced hepatocellular
carcinoma previously treated with sorafenib (KEYNOTE-224): A
non-randomised, open-label phase 2 trial. Lancet Oncol. 19:940–952.
2018. View Article : Google Scholar
|
|
7
|
Eso Y and Marusawa H: Novel approaches for
molecular targeted therapy against hepatocellular carcinoma.
Hepatol Res. 48:597–607. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sia D, Jiao Y, Martinez-Quetglas I, Kuchuk
O, Villacorta-Martin C, Castro de Moura M, Putra J, Camprecios G,
Bassaganyas L, Akers N, et al: Identification of an immune-specific
class of hepatocellular carcinoma, based on molecular features.
Gastroenterology. 153:812–826. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Llovet JM, Montal R, Sia D and Finn RS:
Molecular therapies and precision medicine for hepatocellular
carcinoma. Nat Rev Clin Oncol. 15:599–616. 2018. View Article : Google Scholar
|
|
10
|
Pinyol R, Sia D and Llovet JM: Immune
exclusion-Wnt/CTNNB1 class predicts resistance to immunotherapies
in HCC. Clin Cancer Res. 25:2021–2023. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Harding JJ, Nandakumar S, Armenia J,
Khalil DN, Albano M, Ly M, Shia J, Hechtman JF, Kundra R, El Dika
I, et al: Prospective genotyping of hepatocellular carcinoma:
Clinical Implications of next-generation sequencing for matching
patients to targeted and immune therapies. Clin Cancer Res.
25:2116–2126. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chen L, Zhou Q, Liu J and Zhang W: CTNNB1
alternation is a potential biomarker for immunotherapy prognosis in
patients with hepatocellular carcinoma. Front Immunol.
12:7595652021. View Article : Google Scholar
|
|
13
|
Kuwano A, Tanaka K, Yada M, Nagasawa S,
Morita Y, Masumoto A and Motomura K: Therapeutic efficacy of
lenvatinib for hepatocellular carcinoma with iso-high intensity in
the hepatobiliary phase of Gd-EOB-DTPA-MRI. Mol Clin Oncol.
16:532022. View Article : Google Scholar
|
|
14
|
Johnson PJ, Berhane S, Kagebayashi C,
Satomura S, Teng M, Reeves HL, O'Beirne J, Fox R, Skowronska A,
Palmer D, et al: Assessment of liver function in patients with
hepatocellular carcinoma: A new evidence-based approach-the ALBI
grade. J Clin Oncol. 33:550–558. 2015. View Article : Google Scholar
|
|
15
|
Lencioni R and Llovet JM: Modified RECIST
(mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis.
30:52–60. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hsu HC, Jeng YM, Mao TL, Chu JS, Lai PL
and Peng SY: Beta-catenin mutations are associated with a subset of
low-stage hepatocellular carcinoma negative for hepatitis B virus
and with favorable prognosis. Am J Pathol. 157:763–770. 2000.
View Article : Google Scholar
|
|
17
|
Zucman-Rossi J, Benhamouche S, Godard C,
Boyault S, Grimber G, Balabaud C, Cunha AS, Bioulac-Sage P and
Perret C: Differential effects of inactivated Axin1 and activated
beta-catenin mutations in human hepatocellular carcinomas.
Oncogene. 26:774–780. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tsujikawa H, Masugi Y, Yamazaki K, Itano
O, Kitagawa Y and Sakamoto M: Immunohistochemical molecular
analysis indicates hepatocellular carcinoma subgroups that reflect
tumor aggressiveness. Hum Pathol. 50:24–33. 2016. View Article : Google Scholar
|
|
19
|
Ueno A, Masugi Y, Yamazaki K, Komuta M,
Effendi K, Tanami Y, Tsujikawa H, Tanimoto A, Okuda S, Itano O, et
al: OATP1B3 expression is strongly associated with Wnt/β-catenin
signalling and represents the transporter of gadoxetic acid in
hepatocellular carcinoma. J Hepatol. 61:1080–1087. 2014. View Article : Google Scholar
|
|
20
|
Nguyen TB, Roncalli M, Di Tommaso L and
Kakar S: Combined use of heat-shock protein 70 and glutamine
synthetase is useful in the distinction of typical hepatocellular
adenoma from atypical hepatocellular neoplasms and
well-differentiated hepatocellular carcinoma. Mod Pathol.
29:283–292. 2016. View Article : Google Scholar
|
|
21
|
He S and Tang S: WNT/β-catenin signaling
in the development of liver cancers. Biomed Pharmacother.
132:1108512020. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Nhieu JT, Renard CA, Wei Y, Cherqui D,
Zafrani ES and Buendia MA: Nuclear accumulation of mutated
beta-catenin in hepatocellular carcinoma is associated with
increased cell proliferation. Am J Pathol. 155:703–710. 1999.
View Article : Google Scholar
|
|
23
|
Cadoret A, Ovejero C, Terris B, Souil E,
Lévy L, Lamers WH, Kitajewski J, Kahn A and Perret C: New targets
of beta-catenin signaling in the liver are involved in the
glutamine metabolism. Oncogene. 21:8293–8301. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Loeppen S, Schneider D, Gaunitz F,
Gebhardt R, Kurek R, Buchmann A and Schwarz M: Overexpression of
glutamine synthetase is associated with beta-catenin-mutations in
mouse liver tumors during promotion of hepatocarcinogenesis by
phenobarbital. Cancer Res. 62:5685–5688. 2002.PubMed/NCBI
|
|
25
|
Aoki T, Nishida N and Kudo M: Clinical
significance of the duality of Wnt/β-catenin signaling in human
hepatocellular carcinoma. Cancers (Basel). 14:4442022. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ferrara N, Hillan KJ and Novotny W:
Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody
for cancer therapy. Biochem Biophys Res Commun. 333:328–235. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Finn RS, Bentley G, Britten CD, Amado R
and Busuttil RW: Targeting vascular endothelial growth factor with
the monoclonal antibody bevacizumab inhibits human hepatocellular
carcinoma cells growing in an orthotopic mouse model. Liver Int.
29:284–290. 2009. View Article : Google Scholar
|
|
28
|
Siegel AB, Cohen EI, Ocean A, Lehrer D,
Goldenberg A, Knox JJ, Chen H, Clark-Garvey S, Weinberg A, Mandeli
J, et al: Phase II trial evaluating the clinical and biologic
effects of bevacizumab in unresectable hepatocellular carcinoma. J
Clin Oncol. 26:2992–2998. 2008. View Article : Google Scholar
|
|
29
|
Boige V, Malka D, Bourredjem A, Dromain C,
Baey C, Jacques N, Pignon JP, Vimond N, Bouvet-Forteau N, De Baere
T, et al: Efficacy, safety, and biomarkers of single-agent
bevacizumab therapy in patients with advanced hepatocellular
carcinoma. Oncologist. 17:1063–1072. 2012. View Article : Google Scholar
|
|
30
|
Finn RS and Zhu AX: Targeting angiogenesis
in hepatocellular carcinoma: Focus on VEGF and bevacizumab. Expert
Rev Anticancer Ther. 9:503–509. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
Motz GT, Santoro SP, Wang LP, Garrabrant
T, Lastra RR, Hagemann IS, Lal P, Feldman MD, Benencia F and Coukos
G: Tumor endothelium FasL establishes a selective immune barrier
promoting tolerance in tumors. Nat Med. 20:607–615. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Roland CL, Dineen SP, Lynn KD, Sullivan
LA, Dellinger MT, Sadegh L, Sullivan JP, Shames DS and Brekken RA:
Inhibition of vascular endothelial growth factor reduces
angiogenesis and modulates immune cell infiltration of orthotopic
breast cancer xenografts. Mol Cancer Ther. 8:1761–1771. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Voron T, Colussi O, Marcheteau E, Pernot
S, Nizard M, Pointet AL, Latreche S, Bergaya S, Benhamouda N,
Tanchot C, et al: VEGF-A modulates expression of inhibitory
checkpoints on CD8+ T cells in tumors. J Exp Med.
212:139–148. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sasaki R, Nagata K, Fukushima M, Haraguchi
M, Miuma S, Miyaaki H, Soyama A, Hidaka M, Eguchi S, Shigeno M, et
al: Evaluating the role of hepatobiliary phase of gadoxetic
acid-enhanced magnetic resonance imaging in predicting treatment
impact of lenvatinib and atezolizumab plus bevacizumab on
unresectable hepatocellular carcinoma. Cancers (Basel). 14:8272022.
View Article : Google Scholar : PubMed/NCBI
|
